Comparison of comorbidities and adverse events in dermatology and rheumatology patients prescribed tofacitinib: A retrospective analysis

J Am Acad Dermatol. 2024 Mar;90(3):659-662. doi: 10.1016/j.jaad.2023.11.027. Epub 2023 Nov 24.

¹ The Ronald O. Perelman Department of Dermatology, NYU Grossman School of Medicine, New York, New York.
² Department of Biostatistics, NYU School of Global Public Health, New York, New York.
³ Division of Dermatology, Department of Internal Medicine, Hackensack Meridian School of Medicine, Nutley, New Jersey.
⁴ The Ronald O. Perelman Department of Dermatology, NYU Grossman School of Medicine, New York, New York; Leon H. Charney Division of Cardiology, Department of Medicine, NYU Grossman School of Medicine, New York, New York.
⁵ The Ronald O. Perelman Department of Dermatology, NYU Grossman School of Medicine, New York, New York. Electronic address: theodora.karagounis@nyulangone.org.

No abstract available

Keywords: JAK-STAT inhibitors; cardiovascular adverse events; drug safety; infection; medication adverse effects; tofacitinib.

MeSH terms